Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, has acquired the worldwide rights to Nascobal nasal spray from QOL Medical, a specialty pharmaceutical company.
Subscribe to our email newsletter
Under the terms of the all cash transaction, Strativa Pharmaceuticals will pay QOL Medical $54.5 million for the worldwide rights to Nascobal nasal spray. Nascobal nasal spray will be manufactured by Par, which also acquired the MDRNA facility where the product is manufactured.
Nascobal nasal spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency. It is believed to be the first and only once-weekly, self-administered alternative to B12 injections.
John MacPhee, president of Strativa, said: “We believe that Nascobal nasal spray offers important benefits to people with a vitamin B12 deficiency. Given the large size of the prescription vitamin B12 market and Strativa’s sales and marketing expertise, we believe that Nascobal is poised for significant growth.”